Kristi Rosa

Associate Editorial Director, OncLive®
Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. She helped launch the rapidly growing infectious disease news resource Contagion, strengthened the Rare Disease Report, of HCPLive, and now oversees OncLive and its flagship publication OncologyLive. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com

Articles

Five Under 5: Top Oncology Videos for the Week of 4/27

May 4th 2025

The top 5 OncLive videos of the week cover insights in colorectal cancer, prostate cancer, myeloma, renal cell carcinoma, and urothelial carcinoma.

The OncFive: Top Oncology Articles for the Week of 4/27

May 3rd 2025

The FDA issues a CRL to a glioma imaging agent, an sBLA seeking approval of an epcoritamab triplet in follicular lymphoma is planned for submission, and more.

OncLive’s FDA Approval Report: The Regulatory Rundown for April 2025

May 1st 2025

Here is your snapshot for all therapeutic options that were cleared by the FDA in April 2025 spanning tumor types.

Adjuvant Aumolertinib Boosts DFS in Stage II-IIIB, EGFR-Mutated NSCLC

April 30th 2025

Adjuvant aumolertinib improved disease-free survival in complete resected stage II to IIIB non–small cell lung cancer harboring EGFR mutations.

Lung Cancer Experts Highlight the Significance and Limitations of ADCs

April 30th 2025

Lung cancer experts discuss successes and hesitations regarding the evolving use of antibody-drug conjugates in non–small cell lung cancer.

SYN818 Shows Favorable Safety Profile in Locally Advanced or Metastatic Solid Tumors

April 29th 2025

A phase 1b trial examining SYN818 plus olaparib in patients with solid tumors will be conducted in the second half of 2025.

ICT01 Plus Azacitidine and Venetoclax Shows Early Evidence of Antitumor Activity in AML

April 29th 2025

A low dose of ICT01 added to combination therapy with azacitidine and venetoclax proved active and safe as frontline therapy in patients with AML.

Padeliporfin VTP Therapy Yields Complete Responses With Manageable Safety in Low-Grade, Upper Tract Urothelial Cancer

April 29th 2025

Padeliporfin vascular targeted photodynamic therapy was safe and generated responses in low-grade, upper tract urothelial cancer.

TMPRSS2-ERG Shows Distinct Molecular Landscape in TALAPRO-2 Population With mCRPC

April 28th 2025

Patients with mCRPC enrolled in the phase 3 TALAPRO-2 trial harboring TMPRSS2-ERG fusions in ctDNA had a distinct tumor molecular profile vs those without.

Talazoparib Plus Enzalutamide Improves rPFS Regardless of AR Alteration Status in mCRPC

April 28th 2025

Talazoparib plus enzalutamide improved rPFS vs placebo plus enzalutamide in patients with mCRPC with or without AR alterations.

TARA-002 Showcases Early Clinical Activity in BCG-Naive and -Unresponsive High-Risk NMIBC

April 27th 2025

Interim data from a phase 2 study support the potential of TARA-002 as an intravesical immunotherapy in high-risk NMIBC.

Zoldonrasib Shows Encouraging Early Antitumor Activity in KRAS G12D–Mutated NSCLC

April 27th 2025

Zoldonrasib demonstrates early promise in patients with KRAS G12D–mutated non–small cell lung cancer.

UGN-102 May Represent Alternative to TURBT in Recurrent Low-Grade Intermediate-Risk NMIBC

April 27th 2025

UGN-102 elicits robust responses with acceptable tolerability in recurrent low-grade intermediate-risk non–muscle-invasive bladder cancer.

Five Under 5: Top Oncology Videos for the Week of 4/20

April 27th 2025

The top 5 OncLive videos of the week cover insights in chronic lymphocytic leukemia, ovarian cancer, multiple myeloma, and large B-cell lymphoma.

UGN-301 Shows Early Tolerability in Recurrent Non–Muscle-Invasive Bladder Cancer

April 26th 2025

Continued evaluation of UGN-301 in patients with recurrent NMIBC is warranted.

The OncFive: Top Oncology Articles for the Week of 4/20

April 26th 2025

Penpulimab gets green light from FDA for nasopharyngeal carcinoma, sacituzumab govitecan combination boosts PFS in TNBC, and more.

Moving the Needle in Undifferentiated Pleomorphic Sarcoma: Conclusions

April 20th 2025

In this episode, experts highlight the key takeaways from the Stand Up to Cancer SARC 032 study and its clinical implications.

Five Under 5: Top Oncology Videos for the Week of 4/13

April 20th 2025

The top 5 OncLive videos of the week cover insights in multiple myeloma, AL amyloidosis, myelofibrosis, breast cancer, and sarcoma.

Moving the Needle in Undifferentiated Pleomorphic Sarcoma: Multidisciplinary Collaboration

April 19th 2025

In this episode, experts discuss the landmark SARC 032 study, highlighting the importance of multidisciplinary collaboration.

The OncFive: Top Oncology Articles for the Week of 4/13

April 19th 2025

Nogapendekin alfa inbakicept sBLA in NMIBC has been filed to FDA for review, a bexmarilimab combination elicits responses in MDS, and more from OncLive.